Genmab (GMAB) said Monday new cohort data from its phase 1/2 trial of rinatabart sesutecan to treat patients with advanced endometrial cancer showcased "encouraging" anti-tumor activity and a 47.1% confirmed objective response rate at a dosage of 120 milligrams per square meter, every three weeks.

Participants who received the 100 milligrams per square meter dosage recorded a 50% confirmed objective response rate after a median follow-up of 7.7 months and two complete responses, according to the biotechnology company.

The median duration of response was not reached for both dosage levels, according to Genmab.

Common adverse events included diarrhea, dyspnea, headache, nausea, and urinary tract infection. Hematologic adverse events were managed without significant dose reduction, the company said.

The trial data were presented at the 2025 American Society of Clinical Oncology meeting in Chicago, Illinois.

Shares were up 4.2% in recent trading.

Price: 21.84, Change: +0.89, Percent Change: +4.22